Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2458
Approval and Launch of Affordable Generic of Pemetrexed in Market is Expected to Increase its Adoption
Alimta is a patented drug of Eli Lilly and Company and is protected by a vitamin regimen patent (2021), and pediatric exclusivity (2022) in the U.S., vitamin regimen patent (2021) in major European countries, and patents covering use to treat cancer concomitantly with vitamins (2021) in the Japan.
However, Eli Lilly and Company’s compound patent for Alimta expired in the U.S. in January 2017, and expired in major European countries and Japan in December 2015.
Various other key players have gained regulatory approval for the generic versions of pemetrexed and are expected to launch during the forecast period. Launch of generic version at low price is expected to rise adoption of the drug, which in turn will drive pemetrexed market growth over forecast period.
For instance, in July 2018, the German Federal Patent Court declared the German section of European patent EP 1 313 508 for Alimta, void. Following this, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.
Furthermore, Eli Lilly and Company is dedicated in frequent research and development in order to expand the indication of Alimta and to generate high revenue benefits.
Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others.